Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway

Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway

Background: Mesenchymal stem cells (MSCs) are promising candidates for tissue regeneration and disease treatment. However, long-term in vitro passaging leads to stemness loss of MSCs, resulting in failure of MSC therapy. This study investigated whether the combination of melatonin and human umbilica...

Full description

Bibliographic Details
Main Authors: Aierken, A. (Author), Cheng, X. (Author), Du, X. (Author), Enkhbaatar, B.B (Author), He, X. (Author), Hua, J. (Author), Jia, W. (Author), Kou, Z. (Author), Li, B. (Author), Li, N. (Author), Liu, P. (Author), Peng, S. (Author), Shen, Q. (Author), Tan, N. (Author), Wang, C. (Author), Wang, R. (Author), Wu, X. (Author), Yu, S. (Author), Zhang, J. (Author), Zhang, M. (Author), Zhang, R. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Human umbilical cord mesenchymal stem cell (hUC-MSC)
Melatonin
PI3K/AKT signaling pathway
Type II diabetes mellitus
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items